You're now repeating the same dirge, so in the bin for you. I'm all for different opinions, but yours has got a bit excessive now... |
Chica
"How low will the market take the share price"
I think to around 10p
The company newsflow has been as expected.
Oh look, Nexn thread busy, HVO quiet. Looks like 1gw and his mates have moved back to ramping nexn, another with a highly questionable business model (their peers refuse to use the same business model) and several different name changes. The share price there has crashed multiple times over the years.
How many multiple ids do you have 1gw? |
ali47fish,
I would say not really new, but news.
However if this biomarker is just out there, not sure of the significance to HVO, if we had some sort of discovery ownership then there might be a value, however I suspect because of the consortium any value in this new biomarker won't be HVO's.
So good news story but no particular relevance to Challenge studies, more to diagnostic companies who can use this new biomarker for tests. |
It's not news,it's filler...
Bottom line for Hvivo right now is how they are going to beat 2024 revenue of £62 million in 2025.
And
If they don't how low will the market take the share price |
Yes. COVID/ respiratory diseases are a very popular area of drug development hence why the RSV challenge model is popular with clients. At £10 million + a pop for a challenge study this will bring in plenty of cash going forward. |
is this significant and new though |
 A new peer review paper has been published in Nature Communications titled "SARS-CoV-2 human challenge reveals single-gene blood transcriptional biomarkers that discriminate early and late phases of acute respiratory viral infections". This publication builds on the groundbreaking insights from the world's first COVID-19 characterisation trial we conducted in 2021. Please see link to RNS available here: https://www.londonstockexchange.com/news-article/HVO/covid-19-study-published-in-nature-communications/16807788 The study identified key biomarkers in the blood activated, not only in SARS-CoV-2 infection but also in other respiratory viruses, that can identify and distinguish between the early and late phases of infection. These biomarkers could provide a basis for advancements in infection diagnosis and management in early and late-stage infections. Human challenge trials allow researchers to observe infection progression, particularly in the early stages, in detail that would not be possible with a traditional field study. We are delighted to see that hVIVO's impactful contributions during the COVID pandemic continue to enhance understanding of the immune response to SARS-CoV-2 infection and other respiratory viruses. Don't hesitate to contact me should you have any |
COVID/respiratory diseases challenge agent should prove popular with clients |
Could be a woman |
Funny I had the impression Pogue was an elderly bloke by his posting here.
I'd have thought his so called colleagues (who apparently he was out on the lash with)would have been filtered🤔28527; |
Pogue filtered. Pathetic when someone has blinkers on and won't see alternative views. |
ltbh often quoted but incorrectly.
Actually means: long term buy and hope.
Because very very few people have the knowledge, analysis and resources of Buffett. |
as long as it takes no rush at all |
I suspect you are in for a long wait .. as I was .. I waited for 4 years before selling .
Hope it works out for you . |
long term not trading simple |
And in any case,it's 2025 that's important ..2028 is meaningless at this time .. unless your nuts that is .. |
quote he is very bullish of getting 100m revenue by 2028 ....me i will be buying few more as time goes by |
Huge difference Chica .. but they see what they want to see.. |
He did not say they were on 'track' for 2028 he said 'aiming'
Big difference |
Chica, as we stand it's going to take a miracle to be flat .
Even if they sign those other contracts expected since the summer it's unlikely that the work will be all done in 2025 ... we know the lead times etc .
I can't see how Mo can get out of this one .. unless he can pull a huge rabbit out of the hat .. because nothing less than that is required.. |
well he says it 5.45 seconds in of the new proactive interview boooom time thats all i need to know here |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
